Drug intelligence / Profile preview

GCS004

Development stage: Preclinical
Lead developer: Glen Clova Scientific
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

GCS004 is an investigational virus-like particle (VLP)-based therapeutic biologic being developed by Glen Clova Scientific for the treatment of oncology. Originating from research at the University of Dundee, the candidate utilizes Glen Clova's proprietary active biologic platform, which displays target antigens on the surface of structurally stable VLPs to stimulate a targeted immune response. GCS004 is currently in the discovery stage of development, and its specific molecular target and oncology indications remain undisclosed.

Beyond the preview

Go deeper on GCS004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GCS004.

Explore the full profile